A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...

Bailard Inc. increased its stake in Regeneron Pharmaceuticals by 10.1% in Q4, raising its holdings to 13,422 shares.

NEW YORK, NY / ACCESS Newswire / March 1, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want ...

Feb. 24 meeting of the full Nassau County Legislature, Deputy Minority Leader Arnold W. Drucker honored District 16's seven ...

Sterling Investment Advisors Ltd. increased its holdings in Regeneron Pharmaceuticals by 23.5% during Q4. The firm now owns 3 ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

Secondly, to support the stock price, Regeneron management announced the authorization of an additional $3 billion, which will go towards a share buyback program. The New York-based company ...

On April 10, 2024, the U.S. Department of Justice ("DOJ") announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report ...

Such statements may include, but are not limited to those related to Regeneron and its products and business, financial forecast and guidance, development programs and related anticipated ...

Given the accelerating sales growth of LIBTAYO and stabilization in the EYLEA franchise, investors bid up the price of Regeneron's stock by +4.5% on Tuesday. The company's robust performance makes ...